Skip to main content

Table 4 18F-FDG PET/CT best response

From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

nab-Paclitaxel Dose Cohorta, n (%)

CMR

PMR

SMD

PMD

100 mg/m2 (n = 13)

3 (23)

7 (54)

3 (23)

0

125 mg/m2 (n = 38)

13 (34)

25 (66)

0

0

  1. a1 patient received nab-paclitaxel 150 mg/m2 and their best response by 18F-FDG PET/CT was CMR
  2. CMR complete metabolic response, CT computed tomography, 18 F-FDG [18F]2-fluoro-2-deoxyglucose, PET positron emission tomography, PMD progressive metabolic disease, PMR partial metabolic response, SMD stable metabolic disease